Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy.
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 21, doi. 10.1007/s40259-022-00573-3
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2023 AND VI 37 AND IP 1
Results: 10
1
2
Current Developments in the Preclinical and Clinical use of Natural Killer T cells.
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 57, doi. 10.1007/s40259-022-00572-4
- By:
- Publication type:
- Article
3
Malaysian Hospital Pharmacists' Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey.
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 109, doi. 10.1007/s40259-022-00571-5
- By:
- Publication type:
- Article
4
Acknowledgement to Referees.
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 1, doi. 10.1007/s40259-022-00570-6
- Publication type:
- Article
5
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 35, doi. 10.1007/s40259-022-00569-z
- By:
- Publication type:
- Article
6
Complement Inhibition in Kidney Transplantation: Where Are We Now?
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 5, doi. 10.1007/s40259-022-00567-1
- By:
- Publication type:
- Article
7
Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations.
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 99, doi. 10.1007/s40259-022-00566-2
- By:
- Publication type:
- Article
8
Correction to: First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
9
Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase<sup>®</sup>).
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 73, doi. 10.1007/s40259-022-00564-4
- By:
- Publication type:
- Article
10
Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial.
- Published in:
- BioDrugs, 2023, v. 37, n. 1, p. 89, doi. 10.1007/s40259-022-00563-5
- By:
- Publication type:
- Article